- Home
- / Larimar Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Larimar Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$7.8
2024-10-29
Market Capitalization
$496.4 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 8.1M | 19.2M | 18.3M | 12.2M | 13.2M | 16.2M | 11.4M | 12.1M | 12.3M | 14.1M | 17.6M | 18.3M |
| Operating expense total | 35.5M | 73.8M | 58.2M | 53.0M | 61.1M | 40.1M | 42.8M | 36.5M | 90.9M | 172.5M | ||
| EBIT | (35.5M) | (73.8M) | (58.2M) | (53.0M) | (61.1M) | (45.7M) | (42.8M) | (50.5M) | (36.5M) | (41.8M) | (90.9M) | (172.5M) |
| Investment income | 28.0K | 438.0K | 894.0K | 996.0K | 1.9M | |||||||
| Interest income | 2.0M | |||||||||||
| Pre tax profit | (36.5M) | (74.3M) | (57.9M) | (52.0M) | (61.4M) | (45.4M) | (42.5M) | (50.6M) | (35.4M) | (36.9M) | (80.6M) | (165.7M) |
| Net Income | (36.5M) | (74.3M) | (57.9M) | (52.0M) | (61.4M) | (45.4M) | (42.5M) | (50.6M) | (35.4M) | (36.9M) | (80.6M) | (165.7M) |
| EPS | (1.4) | (1.3) |